Review



primary antibodies against osteocalcin (ocn)  (Santa Cruz Biotechnology)


Bioz Verified Symbol Santa Cruz Biotechnology is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    Santa Cruz Biotechnology primary antibodies against osteocalcin (ocn)
    Primary Antibodies Against Osteocalcin (Ocn), supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against osteocalcin (ocn)/product/Santa Cruz Biotechnology
    Average 90 stars, based on 1 article reviews
    primary antibodies against osteocalcin (ocn) - by Bioz Stars, 2026-03
    90/100 stars

    Images



    Similar Products

    94
    Bioss primary antibodies against osteocalcin ocn
    Knockdown of enhancer of zeste homolog 2 inhibits steo/dentinogenic differentiation potential of human apical papillary stem cells. A: Quantitative polymerase chain reaction showed that the expression of enhancer of zeste homolog 2 (EZH2) was inhibited in human apical papillary stem cells (hSCAPs); B: Western blot analysis confirmed the knockdown of EZH2 in hSCAPs; C: Knockdown of EZH2 decreased alkaline phosphatase activity in hSCAPs; D and E: Alizarin red staining and quantitative calcium analysis demonstrated that knockdown of EZH2 inhibited mineralization in hSCAPs; F-H: Quantitative polymerase chain reaction showed that knockdown of EZH2 downregulated mRNA expression levels of bone sialoprotein (F), dentin sialophosphoprotein (G), and <t>osteocalcin</t> (H) in hSCAPs. GAPDH and ACTB was used as the internal controls. Data are presented as the mean ± SD ( n = 3). Statistical analysis was performed using Student’s t -test. a P ≤ 0.05, b P ≤ 0.01, c P ≤ 0.001. EZH2: Enhancer of zeste homolog 2; BSP: Bone sialoprotein; DSPP: Dentin sialophosphoprotein; <t>OCN:</t> Osteocalcin.
    Primary Antibodies Against Osteocalcin Ocn, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against osteocalcin ocn/product/Bioss
    Average 94 stars, based on 1 article reviews
    primary antibodies against osteocalcin ocn - by Bioz Stars, 2026-03
    94/100 stars
      Buy from Supplier

    90
    Santa Cruz Biotechnology primary antibodies against osteocalcin (ocn)
    Knockdown of enhancer of zeste homolog 2 inhibits steo/dentinogenic differentiation potential of human apical papillary stem cells. A: Quantitative polymerase chain reaction showed that the expression of enhancer of zeste homolog 2 (EZH2) was inhibited in human apical papillary stem cells (hSCAPs); B: Western blot analysis confirmed the knockdown of EZH2 in hSCAPs; C: Knockdown of EZH2 decreased alkaline phosphatase activity in hSCAPs; D and E: Alizarin red staining and quantitative calcium analysis demonstrated that knockdown of EZH2 inhibited mineralization in hSCAPs; F-H: Quantitative polymerase chain reaction showed that knockdown of EZH2 downregulated mRNA expression levels of bone sialoprotein (F), dentin sialophosphoprotein (G), and <t>osteocalcin</t> (H) in hSCAPs. GAPDH and ACTB was used as the internal controls. Data are presented as the mean ± SD ( n = 3). Statistical analysis was performed using Student’s t -test. a P ≤ 0.05, b P ≤ 0.01, c P ≤ 0.001. EZH2: Enhancer of zeste homolog 2; BSP: Bone sialoprotein; DSPP: Dentin sialophosphoprotein; <t>OCN:</t> Osteocalcin.
    Primary Antibodies Against Osteocalcin (Ocn), supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against osteocalcin (ocn)/product/Santa Cruz Biotechnology
    Average 90 stars, based on 1 article reviews
    primary antibodies against osteocalcin (ocn) - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Proteintech primary antibody against ocn
    Biocompatibility and osteogenic differentiation potential of MC3T3-E1 seeded on 2D/3D SP (1:3) /GelSP (1:4) scaffolds. (a) The cell distribution inside 3DSP (1:3) /GelSP (1:4) . Dil-labeled ATDC5(red) were seeded on the SP (1:3) layer, and Dio-labeled MC3T3-E1(green) were seeded on the GelSP (1:4) layer of 3DSP (1:3) /GelSP (1:4) for 7days. (b) Cell proliferation of MC3T3-E1 seeded on 2D/3D SP (1:3) /GelSP (1:4) scaffolds at days 1, 3, and 7, as measured by the CCK-8 assay. (c) The viability of MC3T3-E1 seeded on 2D/3D SP (1:3) /GelSP (1:4) scaffolds by live/dead staining and its 3D fluorescent images for 3 days. (d) Cytoskeleton staining of MC3T3-E1 cultured on different scaffolds for 3 days. (e–g) The relative mRNA expression levels of OPN, Runx2, and <t>OCN</t> of MC3T3-E1 seeded on 2D/3D SP (1:3) /GelSP (1:4) scaffolds for 14 days. (h) Immunofluorescence images of osteocalcin (OCN) in MC3T3-E1 seeded on 2D/3D SP (1:3) /GelSP (1:4) scaffolds. (∗p < 0.05. ∗∗p < 0.01. ∗∗∗p < 0.001).
    Primary Antibody Against Ocn, supplied by Proteintech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibody against ocn/product/Proteintech
    Average 90 stars, based on 1 article reviews
    primary antibody against ocn - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Servicebio Inc primary antibodies against osteocalcin (ocn)
    Abbreviations: AgÅPs: Ångstrom-scale silver particles; <t>OCN:</t> <t>Osteocalcin;</t> TRAP: Tartrate resistant acid phosphatase.
    Primary Antibodies Against Osteocalcin (Ocn), supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against osteocalcin (ocn)/product/Servicebio Inc
    Average 90 stars, based on 1 article reviews
    primary antibodies against osteocalcin (ocn) - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Huabio Inc primary antibodies against ocn er191920
    Abbreviations: AgÅPs: Ångstrom-scale silver particles; <t>OCN:</t> <t>Osteocalcin;</t> TRAP: Tartrate resistant acid phosphatase.
    Primary Antibodies Against Ocn Er191920, supplied by Huabio Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against ocn er191920/product/Huabio Inc
    Average 90 stars, based on 1 article reviews
    primary antibodies against ocn er191920 - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Wanleibio primary antibodies against osteocalcin (ocn) wlh4378
    Abbreviations: AgÅPs: Ångstrom-scale silver particles; <t>OCN:</t> <t>Osteocalcin;</t> TRAP: Tartrate resistant acid phosphatase.
    Primary Antibodies Against Osteocalcin (Ocn) Wlh4378, supplied by Wanleibio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against osteocalcin (ocn) wlh4378/product/Wanleibio
    Average 90 stars, based on 1 article reviews
    primary antibodies against osteocalcin (ocn) wlh4378 - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    ABclonal Biotechnology primary antibodies against ocn a18241
    Abbreviations: AgÅPs: Ångstrom-scale silver particles; <t>OCN:</t> <t>Osteocalcin;</t> TRAP: Tartrate resistant acid phosphatase.
    Primary Antibodies Against Ocn A18241, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against ocn a18241/product/ABclonal Biotechnology
    Average 90 stars, based on 1 article reviews
    primary antibodies against ocn a18241 - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Affinity Biosciences primary antibodies against ocn
    Protective effect of MD on AGEs-induced osteoblasts. (A) Effect of MD on the survival rate of osteoblasts (n = 6); (B) ALP activity in osteoblasts (n = 6); (C) Western blotting results of <t>OCN</t> and RUNX2 in osteoblasts (n = 3). * P < 0.05; ** P < 0.01.
    Primary Antibodies Against Ocn, supplied by Affinity Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against ocn/product/Affinity Biosciences
    Average 90 stars, based on 1 article reviews
    primary antibodies against ocn - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Abmart Inc primary antibodies against rat ocn, bmp2, and alp
    Protective effect of MD on AGEs-induced osteoblasts. (A) Effect of MD on the survival rate of osteoblasts (n = 6); (B) ALP activity in osteoblasts (n = 6); (C) Western blotting results of <t>OCN</t> and RUNX2 in osteoblasts (n = 3). * P < 0.05; ** P < 0.01.
    Primary Antibodies Against Rat Ocn, Bmp2, And Alp, supplied by Abmart Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against rat ocn, bmp2, and alp/product/Abmart Inc
    Average 90 stars, based on 1 article reviews
    primary antibodies against rat ocn, bmp2, and alp - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    90
    Affinity Biosciences primary antibodies against osteocalcin (ocn)
    Protective effect of MD on AGEs-induced osteoblasts. (A) Effect of MD on the survival rate of osteoblasts (n = 6); (B) ALP activity in osteoblasts (n = 6); (C) Western blotting results of <t>OCN</t> and RUNX2 in osteoblasts (n = 3). * P < 0.05; ** P < 0.01.
    Primary Antibodies Against Osteocalcin (Ocn), supplied by Affinity Biosciences, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/primary antibodies against osteocalcin (ocn)/product/Affinity Biosciences
    Average 90 stars, based on 1 article reviews
    primary antibodies against osteocalcin (ocn) - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    Image Search Results


    Knockdown of enhancer of zeste homolog 2 inhibits steo/dentinogenic differentiation potential of human apical papillary stem cells. A: Quantitative polymerase chain reaction showed that the expression of enhancer of zeste homolog 2 (EZH2) was inhibited in human apical papillary stem cells (hSCAPs); B: Western blot analysis confirmed the knockdown of EZH2 in hSCAPs; C: Knockdown of EZH2 decreased alkaline phosphatase activity in hSCAPs; D and E: Alizarin red staining and quantitative calcium analysis demonstrated that knockdown of EZH2 inhibited mineralization in hSCAPs; F-H: Quantitative polymerase chain reaction showed that knockdown of EZH2 downregulated mRNA expression levels of bone sialoprotein (F), dentin sialophosphoprotein (G), and osteocalcin (H) in hSCAPs. GAPDH and ACTB was used as the internal controls. Data are presented as the mean ± SD ( n = 3). Statistical analysis was performed using Student’s t -test. a P ≤ 0.05, b P ≤ 0.01, c P ≤ 0.001. EZH2: Enhancer of zeste homolog 2; BSP: Bone sialoprotein; DSPP: Dentin sialophosphoprotein; OCN: Osteocalcin.

    Journal: World Journal of Stem Cells

    Article Title: EZH2, via an association with KDM2B, modulates osteogenic differentiation of root apical papillary stem cells

    doi: 10.4252/wjsc.v17.i4.103482

    Figure Lengend Snippet: Knockdown of enhancer of zeste homolog 2 inhibits steo/dentinogenic differentiation potential of human apical papillary stem cells. A: Quantitative polymerase chain reaction showed that the expression of enhancer of zeste homolog 2 (EZH2) was inhibited in human apical papillary stem cells (hSCAPs); B: Western blot analysis confirmed the knockdown of EZH2 in hSCAPs; C: Knockdown of EZH2 decreased alkaline phosphatase activity in hSCAPs; D and E: Alizarin red staining and quantitative calcium analysis demonstrated that knockdown of EZH2 inhibited mineralization in hSCAPs; F-H: Quantitative polymerase chain reaction showed that knockdown of EZH2 downregulated mRNA expression levels of bone sialoprotein (F), dentin sialophosphoprotein (G), and osteocalcin (H) in hSCAPs. GAPDH and ACTB was used as the internal controls. Data are presented as the mean ± SD ( n = 3). Statistical analysis was performed using Student’s t -test. a P ≤ 0.05, b P ≤ 0.01, c P ≤ 0.001. EZH2: Enhancer of zeste homolog 2; BSP: Bone sialoprotein; DSPP: Dentin sialophosphoprotein; OCN: Osteocalcin.

    Article Snippet: Immunohistochemical analysis followed established protocols[ ] using primary antibodies against osteocalcin (OCN) (Bioss bs-4917R) and DSPP (Bioss bs10316R).

    Techniques: Knockdown, Real-time Polymerase Chain Reaction, Expressing, Western Blot, Activity Assay, Staining

    Overexpression of enhancer of zeste homolog 2 enhances osteo/dentinogenic differentiation potential of human apical papillary stem cells. A: Quantitative polymerase chain reaction showed that enhancer of zeste homolog 2 (EZH2) was overexpressed in human apical papillary stem cells (hSCAPs); B: Western blot analysis confirmed overexpression of EZH2 in hSCAPs; C: Overexpression of EZH2 increased alkaline phosphatase activity in hSCAPs; D and E: Alizarin red staining and quantitative calcium analysis results demonstrated that overexpression of EZH2 enhanced mineralization in hSCAPs; F-H: Quantitative polymerase chain reaction showed that overexpression of EZH2 upregulated mRNA expression levels of bone sialoprotein (F), dentin sialophosphoprotein (G), and osteocalcin (H) in hSCAPs; I: Hematoxylin-eosin staining and quantitative measurement showed that overexpression of EZH2 promoted bone/dentin-like tissue formation. Scale bar = 100 μm (B: Bone/dentin-like tissues; HA: Hydroxyapatite tricalcium carrier; CT: Connective tissue); J: Immunohistochemical staining and quantitative analysis of dentin sialophosphoprotein and bone sialoprotein. GAPDH and ACTB were used as the internal controls. Data are presented as the mean ± SD ( n = 3). Statistical analysis was performed using Student’s t -test. a P ≤ 0.05, b P ≤ 0.01, c P ≤ 0.001. EZH2: Enhancer of zeste homolog 2; BSP: Bone sialoprotein; DSPP: Dentin sialophosphoprotein; OCN: Osteocalcin.

    Journal: World Journal of Stem Cells

    Article Title: EZH2, via an association with KDM2B, modulates osteogenic differentiation of root apical papillary stem cells

    doi: 10.4252/wjsc.v17.i4.103482

    Figure Lengend Snippet: Overexpression of enhancer of zeste homolog 2 enhances osteo/dentinogenic differentiation potential of human apical papillary stem cells. A: Quantitative polymerase chain reaction showed that enhancer of zeste homolog 2 (EZH2) was overexpressed in human apical papillary stem cells (hSCAPs); B: Western blot analysis confirmed overexpression of EZH2 in hSCAPs; C: Overexpression of EZH2 increased alkaline phosphatase activity in hSCAPs; D and E: Alizarin red staining and quantitative calcium analysis results demonstrated that overexpression of EZH2 enhanced mineralization in hSCAPs; F-H: Quantitative polymerase chain reaction showed that overexpression of EZH2 upregulated mRNA expression levels of bone sialoprotein (F), dentin sialophosphoprotein (G), and osteocalcin (H) in hSCAPs; I: Hematoxylin-eosin staining and quantitative measurement showed that overexpression of EZH2 promoted bone/dentin-like tissue formation. Scale bar = 100 μm (B: Bone/dentin-like tissues; HA: Hydroxyapatite tricalcium carrier; CT: Connective tissue); J: Immunohistochemical staining and quantitative analysis of dentin sialophosphoprotein and bone sialoprotein. GAPDH and ACTB were used as the internal controls. Data are presented as the mean ± SD ( n = 3). Statistical analysis was performed using Student’s t -test. a P ≤ 0.05, b P ≤ 0.01, c P ≤ 0.001. EZH2: Enhancer of zeste homolog 2; BSP: Bone sialoprotein; DSPP: Dentin sialophosphoprotein; OCN: Osteocalcin.

    Article Snippet: Immunohistochemical analysis followed established protocols[ ] using primary antibodies against osteocalcin (OCN) (Bioss bs-4917R) and DSPP (Bioss bs10316R).

    Techniques: Over Expression, Real-time Polymerase Chain Reaction, Western Blot, Activity Assay, Staining, Expressing, Immunohistochemical staining

    Biocompatibility and osteogenic differentiation potential of MC3T3-E1 seeded on 2D/3D SP (1:3) /GelSP (1:4) scaffolds. (a) The cell distribution inside 3DSP (1:3) /GelSP (1:4) . Dil-labeled ATDC5(red) were seeded on the SP (1:3) layer, and Dio-labeled MC3T3-E1(green) were seeded on the GelSP (1:4) layer of 3DSP (1:3) /GelSP (1:4) for 7days. (b) Cell proliferation of MC3T3-E1 seeded on 2D/3D SP (1:3) /GelSP (1:4) scaffolds at days 1, 3, and 7, as measured by the CCK-8 assay. (c) The viability of MC3T3-E1 seeded on 2D/3D SP (1:3) /GelSP (1:4) scaffolds by live/dead staining and its 3D fluorescent images for 3 days. (d) Cytoskeleton staining of MC3T3-E1 cultured on different scaffolds for 3 days. (e–g) The relative mRNA expression levels of OPN, Runx2, and OCN of MC3T3-E1 seeded on 2D/3D SP (1:3) /GelSP (1:4) scaffolds for 14 days. (h) Immunofluorescence images of osteocalcin (OCN) in MC3T3-E1 seeded on 2D/3D SP (1:3) /GelSP (1:4) scaffolds. (∗p < 0.05. ∗∗p < 0.01. ∗∗∗p < 0.001).

    Journal: Materials Today Bio

    Article Title: Bi-phasic integrated silk fibroin/polycaprolactone scaffolds for osteochondral regeneration inspired by the native joint tissue and interface

    doi: 10.1016/j.mtbio.2025.101737

    Figure Lengend Snippet: Biocompatibility and osteogenic differentiation potential of MC3T3-E1 seeded on 2D/3D SP (1:3) /GelSP (1:4) scaffolds. (a) The cell distribution inside 3DSP (1:3) /GelSP (1:4) . Dil-labeled ATDC5(red) were seeded on the SP (1:3) layer, and Dio-labeled MC3T3-E1(green) were seeded on the GelSP (1:4) layer of 3DSP (1:3) /GelSP (1:4) for 7days. (b) Cell proliferation of MC3T3-E1 seeded on 2D/3D SP (1:3) /GelSP (1:4) scaffolds at days 1, 3, and 7, as measured by the CCK-8 assay. (c) The viability of MC3T3-E1 seeded on 2D/3D SP (1:3) /GelSP (1:4) scaffolds by live/dead staining and its 3D fluorescent images for 3 days. (d) Cytoskeleton staining of MC3T3-E1 cultured on different scaffolds for 3 days. (e–g) The relative mRNA expression levels of OPN, Runx2, and OCN of MC3T3-E1 seeded on 2D/3D SP (1:3) /GelSP (1:4) scaffolds for 14 days. (h) Immunofluorescence images of osteocalcin (OCN) in MC3T3-E1 seeded on 2D/3D SP (1:3) /GelSP (1:4) scaffolds. (∗p < 0.05. ∗∗p < 0.01. ∗∗∗p < 0.001).

    Article Snippet: After 14 days of in vitro culture, cells/scaffold complexes were fixed in 4 % paraformaldehyde, permeabilized with 0.1 % Triton X-100 for 10 min, and blocked with 3 % BSA for 1 h. The cells were then incubated with the primary antibody against OCN (Proteintech, China, 1:500) and collagen II (Proteintech, China, 1:500) overnight respectively, followed by 1 h co-incubation with Cy3-conjugated fluorescence secondary antibody (Abclonal, China, 1:200).

    Techniques: Labeling, CCK-8 Assay, Staining, Cell Culture, Expressing, Immunofluorescence

    Immunological assessment of osteochondral defect in vivo at 6 and 12 weeks. Representative images of COL-II (a, b) and OCN (c, d) immunohistochemical staining (The images on the right are magnified views of the left images, with black arrows indicating the boundary between normal cartilage (N) and repaired cartilage (R), V represents vessel, S represents incompletely degraded scaffolds).

    Journal: Materials Today Bio

    Article Title: Bi-phasic integrated silk fibroin/polycaprolactone scaffolds for osteochondral regeneration inspired by the native joint tissue and interface

    doi: 10.1016/j.mtbio.2025.101737

    Figure Lengend Snippet: Immunological assessment of osteochondral defect in vivo at 6 and 12 weeks. Representative images of COL-II (a, b) and OCN (c, d) immunohistochemical staining (The images on the right are magnified views of the left images, with black arrows indicating the boundary between normal cartilage (N) and repaired cartilage (R), V represents vessel, S represents incompletely degraded scaffolds).

    Article Snippet: After 14 days of in vitro culture, cells/scaffold complexes were fixed in 4 % paraformaldehyde, permeabilized with 0.1 % Triton X-100 for 10 min, and blocked with 3 % BSA for 1 h. The cells were then incubated with the primary antibody against OCN (Proteintech, China, 1:500) and collagen II (Proteintech, China, 1:500) overnight respectively, followed by 1 h co-incubation with Cy3-conjugated fluorescence secondary antibody (Abclonal, China, 1:200).

    Techniques: In Vivo, Immunohistochemical staining, Staining

    Abbreviations: AgÅPs: Ångstrom-scale silver particles; OCN: Osteocalcin; TRAP: Tartrate resistant acid phosphatase.

    Journal: Biomaterials Translational

    Article Title: Ångstrom-scale silver particle-infused hydrogels eliminate orthopedic implant infections and support fracture healing

    doi: 10.12336/biomatertransl.2025.01.007

    Figure Lengend Snippet: Abbreviations: AgÅPs: Ångstrom-scale silver particles; OCN: Osteocalcin; TRAP: Tartrate resistant acid phosphatase.

    Article Snippet: Immunohistochemical staining was performed using primary antibodies against osteocalcin (OCN) (Cat no.: GB11233, Servicebio, China) with a dilution of 1:300, tumor necrosis factor-alpha (TNF-α) (Cat no.: GB11188, Servicebio, China) with a dilution of 1:800, and interleukin-1 beta (IL-1β) (Cat no.: GB11113, Servicebio, China) with a dilution of 1:400.

    Techniques:

    Note: Statistical significance determined at * p < 0.05 and ** p < 0.01. Abbreviations: AgÅPs: Ångstrom-scale silver particles; E. coli: Escherichia coli ; Gel: Hydrogel; IM: Induced medium ; OCN: Osteocalcin; TRAP: Tartrate resistant acid phosphatase.

    Journal: Biomaterials Translational

    Article Title: Ångstrom-scale silver particle-infused hydrogels eliminate orthopedic implant infections and support fracture healing

    doi: 10.12336/biomatertransl.2025.01.007

    Figure Lengend Snippet: Note: Statistical significance determined at * p < 0.05 and ** p < 0.01. Abbreviations: AgÅPs: Ångstrom-scale silver particles; E. coli: Escherichia coli ; Gel: Hydrogel; IM: Induced medium ; OCN: Osteocalcin; TRAP: Tartrate resistant acid phosphatase.

    Article Snippet: Immunohistochemical staining was performed using primary antibodies against osteocalcin (OCN) (Cat no.: GB11233, Servicebio, China) with a dilution of 1:300, tumor necrosis factor-alpha (TNF-α) (Cat no.: GB11188, Servicebio, China) with a dilution of 1:800, and interleukin-1 beta (IL-1β) (Cat no.: GB11113, Servicebio, China) with a dilution of 1:400.

    Techniques:

    Protective effect of MD on AGEs-induced osteoblasts. (A) Effect of MD on the survival rate of osteoblasts (n = 6); (B) ALP activity in osteoblasts (n = 6); (C) Western blotting results of OCN and RUNX2 in osteoblasts (n = 3). * P < 0.05; ** P < 0.01.

    Journal: Frontiers in Pharmacology

    Article Title: Screening of active components of melastoma dodecandrum lour. against diabetic osteoporosis using cell membrane chromatography-mass spectrometry

    doi: 10.3389/fphar.2024.1450154

    Figure Lengend Snippet: Protective effect of MD on AGEs-induced osteoblasts. (A) Effect of MD on the survival rate of osteoblasts (n = 6); (B) ALP activity in osteoblasts (n = 6); (C) Western blotting results of OCN and RUNX2 in osteoblasts (n = 3). * P < 0.05; ** P < 0.01.

    Article Snippet: Proteins were separated by electrophoresis, transferred to PVDF membranes, and blocked for 2 h. The membranes were incubated overnight at 4°C with primary antibodies against OCN (#DF12303, Affinity Biosciences, 1:2000), RUNX2 (#PB0171, Bosterbio, 1:2000), RAGE (#BM4901, Bosterbio, 1:2000), and GAPDH (#BM3874, Bosterbio, 1:2000).

    Techniques: Activity Assay, Western Blot

    Protective effect of isovitexin on AGEs-induced osteoblasts. (A) Effect of isovitexin on the survival rate of osteoblasts (n = 6); (B) ALP activity in osteoblasts (n = 6); (C) Western blotting results of OCN and RUNX2 in osteoblasts (n = 3). ** P < 0.01.

    Journal: Frontiers in Pharmacology

    Article Title: Screening of active components of melastoma dodecandrum lour. against diabetic osteoporosis using cell membrane chromatography-mass spectrometry

    doi: 10.3389/fphar.2024.1450154

    Figure Lengend Snippet: Protective effect of isovitexin on AGEs-induced osteoblasts. (A) Effect of isovitexin on the survival rate of osteoblasts (n = 6); (B) ALP activity in osteoblasts (n = 6); (C) Western blotting results of OCN and RUNX2 in osteoblasts (n = 3). ** P < 0.01.

    Article Snippet: Proteins were separated by electrophoresis, transferred to PVDF membranes, and blocked for 2 h. The membranes were incubated overnight at 4°C with primary antibodies against OCN (#DF12303, Affinity Biosciences, 1:2000), RUNX2 (#PB0171, Bosterbio, 1:2000), RAGE (#BM4901, Bosterbio, 1:2000), and GAPDH (#BM3874, Bosterbio, 1:2000).

    Techniques: Activity Assay, Western Blot